Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.56
1 Year Target Price $9.56
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 156.71M USD | Price to earnings Ratio - | 1Y Target Price 9.56 |
Price to earnings Ratio - | 1Y Target Price 9.56 | ||
Volume (30-day avg) 4 | Beta 1.63 | 52 Weeks Range 3.60 - 14.16 | Updated Date 08/15/2025 |
52 Weeks Range 3.60 - 14.16 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.25 | Actual -0.38 |
Profitability
Profit Margin -68.87% | Operating Margin (TTM) -60.53% |
Management Effectiveness
Return on Assets (TTM) -40.03% | Return on Equity (TTM) -935.73% |
Valuation
Trailing PE - | Forward PE 4.82 | Enterprise Value 185607817 | Price to Sales(TTM) 2.09 |
Enterprise Value 185607817 | Price to Sales(TTM) 2.09 | ||
Enterprise Value to Revenue 2.48 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 27018900 | Shares Floating 26005900 |
Shares Outstanding 27018900 | Shares Floating 26005900 | ||
Percent Insiders 0.83 | Percent Institutions 26.7 |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd, formerly known as Clinical Cell Culture, was founded in 1993. It is a regenerative medicine company focused on developing and commercializing innovative therapies for skin restoration. A significant milestone was the FDA approval of RECELL Autologous Cell Harvesting Device.
Core Business Areas
- Burn Care: Focuses on providing solutions for burn wound treatment and skin regeneration using the RECELL System.
- Soft Tissue Repair: Explores applications of RECELL technology for various soft tissue repair procedures.
- Vitiligo: Exploring use of RECELL to repigment skin in patients with stable vitiligo
Leadership and Structure
David Keene is the Chief Executive Officer. The company has a typical organizational structure with departments such as R&D, Sales & Marketing, and Operations.
Top Products and Market Share
Key Offerings
- RECELL System: The RECELL System is Avita Medical's flagship product, used for burn wound treatment and skin regeneration. It enables the preparation of Spray-On Skin Cells using a small sample of the patient's own skin. Competitors include conventional skin grafting, Integra LifeSciences, and Mallinckrodt. Market share data is difficult to obtain precisely but RECELL aims to replace and improve on these current treatments for patients with burns. RECELL is in over 100 hospitals in the US
Market Dynamics
Industry Overview
The regenerative medicine industry is rapidly growing, driven by advancements in cell therapies and tissue engineering. Demand is increasing due to aging populations and rising incidence of chronic wounds.
Positioning
Avita Medical is positioned as a leader in spray-on skin cell technology for burn care and skin restoration, with a competitive advantage in autologous cell harvesting.
Total Addressable Market (TAM)
The TAM for burn care and skin regeneration is estimated to be several billion USD globally. Avita is positioned to capture a significant portion of this market with its RECELL technology and expansion into other soft tissue indications.
Upturn SWOT Analysis
Strengths
- FDA-approved RECELL System
- Autologous cell technology reduces risk of rejection
- Positive clinical trial results
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single core product
- High cost compared to traditional treatments
- Limited market penetration
- Reimbursement challenges
Opportunities
- Expansion into new indications (e.g., vitiligo, trauma)
- Geographic expansion into international markets
- Partnerships with hospitals and burn centers
- Development of next-generation RECELL systems
Threats
- Competition from established wound care companies
- Regulatory hurdles for new indications
- Slow adoption of new technologies by clinicians
- Economic downturn impacting hospital budgets
Competitors and Market Share
Key Competitors
- Integra LifeSciences (IART)
- Mallinckrodt (MNK)
Competitive Landscape
Avita Medical's advantage lies in its autologous cell technology, but faces competition from larger companies with established distribution networks.
Growth Trajectory and Initiatives
Historical Growth: Historical growth driven by adoption of RECELL in burn centers.
Future Projections: Future growth projected based on expanded indications and geographic reach.
Recent Initiatives: Recent initiatives include expanding sales force and pursuing new regulatory approvals.
Summary
Avita Medical is a promising company with a unique technology in the burn care space. The RECELL System offers significant advantages, but the company faces challenges related to cost and market penetration. Expansion into new indications and international markets is crucial for future growth and mitigating reliance on a single product. Its success depends on navigating regulatory hurdles and competing effectively with larger, established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (Placeholder)
- Analyst Reports (Placeholder)
- Industry Reports (Placeholder)
Disclaimers:
This analysis is based on available information and is for informational purposes only. It does not constitute financial advice. Financial data is placeholder and requires access to live feeds for accuracy. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | CEO, President & Executive Director Mr. James M. Corbett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 260 | Website https://avitamedical.com |
Full time employees 260 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.